Related references
Note: Only part of the references are listed.Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
Reyes Maria Martin-Rojas et al.
CLINICAL CASE REPORTS (2022)
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Jordan Gauthier et al.
BLOOD (2022)
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
Wolfgang A. Bethge et al.
BLOOD (2022)
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States
Richard T. Maziarz et al.
LEUKEMIA & LYMPHOMA (2022)
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper
Ibai Los-Arcos et al.
INFECTION (2021)
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart et al.
LEUKEMIA (2021)
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center
Cecilia Carpio et al.
LEUKEMIA & LYMPHOMA (2021)
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Gloria Iacoboni et al.
CANCER MEDICINE (2021)
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski et al.
BLOOD (2021)
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Olalekan O. Oluwole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Claire Roddie et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
Martina Pennisi et al.
BLOOD ADVANCES (2021)
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses
Juliet Meir et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Peter A. Riedell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Jie Zhang et al.
ADVANCES IN THERAPY (2020)
Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma
Olalekan O. Oluwole et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2020)
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Frederick L. Locke et al.
BLOOD ADVANCES (2020)
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial
Ulrich Jaeger et al.
BLOOD (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Marcelo C. Pasquini et al.
BLOOD ADVANCES (2020)
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Rakesh Awasthi et al.
BLOOD ADVANCES (2020)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Andrea Kuhnl et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E. Van den Neste et al.
BONE MARROW TRANSPLANTATION (2016)
Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors
Jo-Anne H. Young et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)